FCP 3P1

Drug Profile

FCP 3P1

Alternative Names: CardioRex

Latest Information Update: 29 May 2001

Price : $50

At a glance

  • Originator Forbes Medi-Tech
  • Class Antihyperlipidaemics; Phytostanols
  • Mechanism of Action Cholesterol absorption inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Hypercholesterolaemia

Most Recent Events

  • 29 May 2001 Discontinued-II for Hypercholesterolaemia in USA (PO)
  • 04 Apr 2000 Phase-II clinical trials for Hypercholesterolaemia in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top